KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Cash from Financing Activities (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Cash from Financing Activities data on record, last reported at -$51.7 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 2542.05% year-over-year to -$51.7 million; the TTM value through Dec 2025 reached -$369.6 million, down 2228.82%, while the annual FY2025 figure was -$369.6 million, 2228.82% down from the prior year.
  • Cash from Financing Activities reached -$51.7 million in Q4 2025 per PCRX's latest filing, up from -$257.5 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $361.4 million in Q4 2021 and bottomed at -$257.5 million in Q3 2025.
  • Average Cash from Financing Activities over 5 years is -$27.8 million, with a median of -$2.9 million recorded in 2024.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 5577.27% in 2024, then plummeted 8950.12% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $361.4 million in 2021, then plummeted by 116.19% to -$58.5 million in 2022, then soared by 96.96% to -$1.8 million in 2023, then decreased by 9.89% to -$2.0 million in 2024, then tumbled by 2542.05% to -$51.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were -$51.7 million in Q4 2025, -$257.5 million in Q3 2025, and -$57.5 million in Q2 2025.